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Background: Inborn errors of metabolism (IEMs) have been anecdotally reported in the literature as presenting
with features of cerebral palsy (CP) or misdiagnosed as ‘atypical CP’. A significant proportion is amenable to treatment
either directly targeting the underlying pathophysiology (often with improvement of symptoms) or with the potential
to halt disease progression and prevent/minimize further damage.
Methods: We performed a systematic literature review to identify all reports of IEMs presenting with CP-like symptoms
before 5 years of age, and selected those for which evidence for effective treatment exists.
Results: We identified 54 treatable IEMs reported to mimic CP, belonging to 13 different biochemical categories. A
further 13 treatable IEMs were included, which can present with CP-like symptoms according to expert opinion, but for
which no reports in the literature were identified. For 26 of these IEMs, a treatment is available that targets the primary
underlying pathophysiology (e.g. neurotransmitter supplements), and for the remainder (n = 41) treatment exerts
stabilizing/preventative effects (e.g. emergency regimen). The total number of treatments is 50, and evidence varies
for the various treatments from Level 1b, c (n = 2); Level 2a, b, c (n = 16); Level 4 (n = 35); to Level 4–5 (n = 6); Level
5 (n = 8). Thirty-eight (57%) of the treatable IEMs mimicking CP can be identified by ready available metabolic
screening tests in blood or urine, while the remaining IEMs require more specific and sometimes invasive tests.
Conclusions: Limited by the rare nature of IEMs and incomplete information in the literature, we conclude that (1)
A surprisingly large number of IEMs can present with CP symptoms, as ‘CP mimics’, (2) although individually rare, a
large proportion of these diseases are treatable such that neurological damage can either be reversed or prevented, (3)
clinician awareness of treatable CP mimics is important for appropriate screening, diagnosis, and early intervention, and
(4) systematic studies are required to elucidate the collective frequency of treatable IEMs in CP.
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Cerebral palsy (CP) is defined as a group of non-
progressive disorders of movement and posture, which
cause activity limitations due to disturbances that occurred
in the developing fetal or infant brain [1]. CP is the most
common cause of physical impairment in the pediatric
population with a prevalence of 2–3 per 1000 live births
[2,3]. Risk factors include prematurity, kernicterus/
hyperbilirubinemia, early CNS infection, non-specific fetalCorrespondence: cvankarnebeek@cw.bc.ca
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unless otherwise stated.or maternal infection, intra-partum asphyxia, birth trauma
and intracranial hemorrhage or neonatal encephalitis [4].
However, despite advances in maternal care and obstet-
rical intervention in recent decades, the incidence of CP
has not declined [5]. Characterization of CP is tradition-
ally based on the predominant quality of motor impair-
ment (spastic, dyskinetic, ataxic-hypotonic or mixed) [6],
assessed on standard neurologic examination.
CP is frequently associated with cognitive, behavioral,
and sensory impairments as well as epilepsy [7]. The most
common morbidity, noted in approximately 40-65% of all
children with CP, is intellectual developmental disabil-
ity (IDD), defined by significant delay in two or moretd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Leach et al. Orphanet Journal of Rare Diseases 2014, 9:197 Page 2 of 14
http://www.ojrd.com/content/9/1/197developmental domains at age less than 5 years and an
intelligence quotient of ≤70 at older age. [8]. Children
with co-occurring ID are at increased risk of emotional
and behavioral problems [9] and other chronic health
conditions requiring frequent hospitalizations [10,11]
with a high burden of care and utilization of health
services for individuals with CP and their families [7].
The associated medical expenditures are considerable;
Kancerla et al. [12] showed that annual costs for children
with CP exceed those of children without CP by $15,047
USD and in case of co-occurring ID by $26,617 USD.
Treatment and ultimately prevention of CP (and IDD)
therefore is essential to reduce the emotional and physical
suffering of patients and families, and to reduce the im-
mense health care costs.
Determination of the underlying cause of CP, whether
due to a malformation, injury acquired during the pre-,
peri-, or postnatal period, or a genetic aberration has ob-
vious significance from the point of view of assessment
of risk, counseling of families, and developing prevention
and intervention strategies [13]. The implicit heterogen-
eity of CP poses a challenge for diagnosis and treatment
[14], and the current management of CP follows a symp-
tomatic approach (e.g., baclofen to relieve spasticity; occu-
pational therapy to improve mobility; pain management).
However, there are reports in the literature of inborn
errors of metabolism (IEMs) that present as CP mimics,
many of which are in fact amenable to therapy targeting
the underlying cause that can improve neurological
outcomes. IEMs are a collection of rare genetic diseases
that generally result from a deficiency of an intracellular
component (e.g., an enzyme or transporter) of a metabolic
pathway, resulting in an accumulation of a substrate or
intermediate in a pathway and/or reduced ability to
synthesize essential compounds. Often the central nervous
system (CNS) is affected, leading to neurological disease
[15]. An example is Segawa disease, also called GTPCH1-
deficient dopa-responsive dystonia (GTPCH1-DRD), char-
acterized by dystonia in childhood that is often misdiag-
nosed as CP e.g., [16,17]. This neurotransmitter disorder
can be diagnosed by standard analysis of neurotransmitter
metabolites in the cerebrospinal fluid. Individuals with
GTPCH1-DRD benefit from treatment with BH4 [18],
amine replacement, as well as levodopa. The majority of
treated individuals shows rapid clinical improvement in
both CP-related symptoms (spasticity, dystonia, general
tone) and are able to lead “an entirely normal life” [16].
It is currently unknown how many such treatable
CP-mimics exist, as the evidence has not been system-
atically reviewed. We model the current review after
our Treatable Intellectual Disability Endeavor (TIDE)
study, which published a list of 89 treatable IEMs that
present with an IDD [19], and a diagnostic algorithm
with App [20]. This algorithm has been implementedin more than 400 children with unexplained IDD as part
of the TIDE-BC study at the British Columbia Children’s
Hospital, in Vancouver, Canada, and treatable IEMs were
identified in more than 5% [20], which serves as motiv-
ation for the work presented here.
Methods
We performed the first systematic review to compile
evidence from the literature and clinical expertise of all
IEMs that are known to present with CP symptoms,
with a focus on those that are amenable to causal treat-
ment. We aim to raise awareness of existence of CP
mimics and formulate a diagnostic algorithm to support
clinicians in the effective identification of these IEMs.
We followed the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) statement (http://
www.prisma-statement.org/) [21].
Information sources
A systematic review was performed to identify all reports
of inborn errors of metabolism (IEMs) presenting with CP
symptoms by searching the PubMed database, checking
reference lists of relevant articles and consulting with
experts in the field. We considered only articles that
were published in English, described findings in humans,
and those where full text publication was available electron-
ically through our institution’s subscription. No publication
date restrictions were imposed and articles included in
analyses were published between 1957–2014. The last
search was performed October 15, 2014.
Definitions & Eligibility criteria
We included only studies describing diseases that are
IEMs, which we have previously defined as “genetic dis-
ease involving a disorder of metabolism with confirmation
based on the internationally accepted diagnostic test(s) for
that IEM (gene mutations, enzyme deficiency, or specific
biochemical marker); this term excludes endocrine disor-
ders” [19]. To identify diseases most likely to be misdiag-
nosed as CP (i.e., to exclude adult-onset), we limited our
inclusion to reports where CP symptoms (Table 1) present
before 5 years of age in at least one reported case.
The goal of this systematic review was to identify all
treatable IEMs that present with CP symptoms, rather
than to identify every report. We selected the most reli-
able or comprehensive reference for this publication;
this implies that additional case reports of CP symptoms
for a given IEM beyond those cited here may exist.
Search strategy
The search strategy is outlined in Table 1. Primarily,
combinations of search terms that describe cerebral
palsy symptoms and inborn errors of metabolism were
used to identify relevant articles in the PubMed database
Table 1 Search strategy to systematically review treatable IEMs that present as CP mimics
Search strategy # Treatable CP mimics
1) PubMed search using combinations of
alternative terms to describe the CP
phenotype and IEMs
Definition: Search terms: 27
Cerebral palsy Cerebral palsy, spastic, spasticity, dystonia,
dyskinesia, ataxia, movement disorder, gait
abnormalities, hypoxic(+/−ischemic)
encephalopathy, perinatal asphyxia
Inborn error of metabolism Inborn error of metabolism, metabolic
disease, amino acids, creatine, mitochondria,
neurotransmitter, organic acid, urea cycle, vitamins
2) Manual search Reference lists of articles identified through PubMed
search were manually screened for additional citations.
15
3) Targeted search of known treatable
IEMs causing ID
Diseases listed in the TIDE App (www.treatable-id.org) as
treatable IEMs searched in combination with the above IEM search terms.
12
Total number of IEMs identified 54
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articles, indicating our approach is conservative and our
search terms are effective. Results from all key word
combination searches were pooled and sorted to iden-
tify 472 unique articles (i.e., without duplicate results),
which were then manually screened based on inclusion/
exclusion criteria by the first author (ELL), with duplicate
publications and those that did not meet eligibility criteria
being removed. As well, reference lists of these publica-
tions were screened for additional relevant articles and
these were judged for inclusion using the same criteria.
Finally, to ensure that we have identified all salient IEMs,
we performed another search using known treatable IEMs
listed in a previous publication of treatable IEMs that
present with intellectual disability (ID) [19] in combin-
ation with our search terms describing CP. Initial searches
were performed independently by ELL following review
protocol and all possible studies were compiled into a
table. The generated list of IEMs was reviewed periodically
by experts SS and CvK to confirm data, refine the search
strategy and inclusion criteria.
Data collection
The following information was extracted from each
article: disease name, cerebral palsy symptoms as re-
ported by the original authors, age of symptom onset,
any treatment used (with the dose and frequency) and
the treatment outcome as described by the authors.
For completeness, we later assigned each disease to a
biochemical category and retrieved OMIM identifiers,
underlying genes and pattern of inheritance, appropri-
ate diagnostic test, and standard of care treatment; all
were agreed upon by expert clinicians. Diagnostic tests
were compared with a recent diagnostic algorithm of
treatable IEMs [20] and with accepted clinical practices
(e.g., GeneReviews®). Given the positive experience
with the 2-tiered protocol for the work-up the childwith IDD for treatable IEMs, we have used this as a
basis for the evaluation of the child with CP for similar
conditions.
Characterizing treatment & effects
As most reviewed studies were case reports, the type of
outcome measures varied. We noted whether or not
treatment was implemented and the original author’s
observations on treatment effect. However, due to the
time span of the reviewed publications, some treatments
are now available that were not at the time of the ori-
ginal publication. Therefore, we took a more objective
approach of employing clinical expertise to determine
the standard of care treatment for the systematically
identified CP mimics and categorized them as treatable
versus non-treatable. Causal treatment for this proportion
of conditions has been thoroughly evaluated by us already
[19], and we apply the same treatment recommendations
here. For conditions where treatment was not previously
reviewed by us, we adhered to guidelines for the specific
IEMs and where needed provided expert input, with
consideration for treatments applied in the original case
reports of CP mimics.
Treatment of IEMs can be either ‘primary treatment’,
which targets the pathophysiology at a cellular level and
improves at least the CP features (muscle tone, rigidity,
etc.) plus/minus the cognitive, behavioural, and MRI
features; or ‘stabilizing/preventative treatment’, which halts
decline and/or prevents further damage, especially during
metabolic crises. For example, creatine supplementation
in creatine deficiencies targets the underlying cause of the
IEM and can reverse the features. Several disorders caused
by deficiencies in vitamins or co-factors can show im-
provement in primary features with appropriate supple-
mentation. Examples of stabilizing/preventative treatment
include emergency regimen for fatty acid oxidation disor-
ders, HSCT for lysosomal disorders and dietary restriction
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disorders.
Non-treatable IEMs are those for which treatment of
the underlying cause is not available (i.e., only treatment
of symptoms) or has shown to not be consistently effect-
ive. We summarize currently non-treatable IEMs in the
hope that when treatment does become available, clini-
cians will be aware that these diseases can mimic CP
and can then intervene.
Levels of evidence
Levels of evidence for treatments were evaluated based on
existing level classification by the Centre of Evidence-
Based Medicine (www.cebm.net): Level 1a = Systematic
Review of RCTs, 1b = Individual RCT, 1c = ’All or None’
[=(prolongation of) survival with therapy]; Level 2a = Sys-
tematic Review of Cohort Studies, 2b = Individual Cohort
Study, 2c = ’Outcomes Research’ [focussed on end results
of therapy for chronic conditions, including functioning
and quality of life]; Level 3 = Systematic Review of Case–
Control Studies; Level 4 = Individual Case–Control
Study or Case-series/report; Level 5 = Expert opinion
without critical appraisal; based on physiology, bench
research or first principles.
Expert-identified CP mimics
The authors who are expert clinicians in pediatric IEMs
(CvK & SS) identified 13 additional diseases which they
have designated as CP mimics in their clinical experi-
ence. For the majority of these, the pathophysiology is
identical to IEMs in the same category for which litera-
ture evidence does exist; for example PSPH and PSAT
deficiency which are both characterized by lack of
serine in the brain similar to PGHDH deficiency
(primarily treatable by serine supplements), or urea
cycle defects in which hyperammonemic crises cause
irreversible brain damage (which are preventable via
dietary manipulation and medication), just like OTC
deficiency for which CP-like features have been
described. Likely such diseases have not (yet) been
described to present as CP in the literature, likely due
to the rare frequency and the increasing challenge of
publishing case reports alone. The expert opinion ap-
proach was used, so that also for these IEMs, affected
individuals might also receive the benefit of early
detection and intervention.
Diagnostic algorithm
To provide guidance for the identification of treatable
CP-mimics, we used the 2-tiered algorithm published by
van Karnebeek et al. [19] to identify treatable IEMs in
children presenting with IDD: First tier tests are generally
accessible and offered by most biochemical genetics la-
boratories around the world with reasonable turn-aroundtimes and affordable prices (total costs $567.97 CAD),
including tests in blood (lactate; ammonia; copper;
ceruloplasmin; plasma total homocysteine; plasma amino-
acids, and bloodspot quantitative acylcarnitine profile) and
in urine (creatine metabolites; purines and pyrimidines;
organic acids; oligosaccharides; and glycosaminoglycans).
Each of these screening tests has the potential to specific-
ally identify treatable IEMs, which is then often confirmed
via molecular and/or enzymatic analysis. The 2nd tier re-
quires a more directed, ‘single test per disease’ approach
based on signs and symptoms. In general these tests are
more invasive and more expensive.
Results
Treatable IEMs
Based on the defined inclusion/exclusion criteria, we
identified 54 treatable IEMs reported to mimic CP
(Table 1). These are categorized alphabetically into 13
biochemical categories (Table 2): amino acids (n = 5),
cerebral glucose transport (n = 1), creatine (n = 1), fatty
acid-related processes (n = 3), hyperhomocysteinemia
(n = 2), lipids (n = 1), lysosomal (n = 4), metals (n = 2),
mitochondrial (n = 3), neurotransmission (n = 9), organic
acids (n = 12), urea cycle (n = 4) and vitamins/co-factors
(n = 7). The CP symptoms for each IEM and correspond-
ing reference are described in Additional file 1: Table S1.
A further 13 treatable IEMs were identified by expert cli-
nicians on our team (Table 3) for a total of 67 treatable
CP mimics. Treatment modalities included: dietary re-
striction/supplement, co-factor/-enzyme, vitamin, sub-
strate inhibition, substrate reduction, bone marrow and
hematopoietic stem cell transplant, gene therapy. The
majority of these treatments are accessible and afford-
able. The total number of different treatments is 50, and
evidence varies for the various treatments from Level
1b, c (n = 2); Level 2a, b, c (n = 16); Level 4 (n = 35); to
Level 4–5 (n = 6); Level 5 (n = 8). For 26 (39%) of these
IEMs, a treatment is available that targets the primary
underlying pathophysiology with the potential to improve
CP symptoms; while for the remaining 41 (61%) IEMs,
treatment is available that stabilizes disease or prevents
further damage (e.g., treatment of Succinic semi-aldehyde
dehydrogenase deficiency (SSADH) with Vigabatrin can
stabilize symptoms [22,23]).
Thirty-eight of the 67 disorders (57%) of the treatable
IEMs described in this review can be identified by ‘1st
tier’ metabolic screening tests in blood or urine (Table 4).
The other 29 (43%) require more specific and sometimes
invasive methods (‘2nd tier tests’; Table 5). Of the 1st tier
tests in the Treatable IDD protocol, urine MPS and
urine oligosaccharides are not required for the diagnostic
evaluation of CP for treatable IEMs. Most 1st tier tests
which detect treatable IEMs described in the literature as
CP mimics can also identify ‘treatable IEMs identified by
Table 2 Overview of all 54 treatable IEMs presenting as CP mimics identified through systematic literature review
Biochemical
category
Disease name OMIM# Gene(s) Treatment Effect Level of
evidence
CP symptoms
























Phenylketonuria (PKU) 261600 PAH (AR) Dietary phenylalanine





2a (4) Spastic diplegia
PHGDH deficiency
(Serine deficiency)










606777 SLC2A1 (AR) Ketogenic diet Primary/targeting
underlying
pathophysiology
4 Spasticity, dystonia, ataxia


















































4 Ataxic gait, hypotonia,
extrapyramidal movements,
upper motor neuron signs
Lipids Abetalipoproteinemia 200100 MTTP (AR) Low long-chain fatty acid
diet with fat-soluble vitamin























Table 2 Overview of all 54 treatable IEMs presenting as CP mimics identified through systematic literature review (Continued)




5 Severe spasticity; spastic
paresis, generalized dystonia











4-5 Loss of all gross motor
function measured by CP
scale; ataxia
Neimann-Pick, type C 257220 NPC1, NPC2 Miglustat Stabilizing/preventative
treatment
1b Axial hypotonia, spastic
diparesis, dystonic posturing
of the hands
















4 Spastic paresis; progressive
ataxia and dystonia












Ketogenic diet & thiamine Primary/targeting
underlying
pathophysiology
4 Spastic quadriplegia; dystonia
Neurotransmission Aromatic-L-amino-acid
decarboxylase deficiency




























233910 GCH1 (AR) BH4, amine replacement Primary/targeting
underlying
pathophysiology
4 dx. CP; spastic diplegia
PTPS deficiency (biopterin
deficiency)
261640 PTS (AR) BH4, diet, amine replacement Primary/targeting
underlying
pathophysiology
4 Dystonia; spastic extremities;
generalized dystonia,
choreoathetoid arm
movements & axial hypotonia
Sepiapterin reductase
deficiency
612716 SPR (AR) Amine replacement Primary/targeting
underlying
pathophysiology


























271980 ALDH5A1 (AR) Vigabatrin Stabilizing/preventa e
treatment




















































4 CNS malformations, episodic
ataxia; pyramidal tract signs
Glutaric aciduria type I (GA1)
aka glutaryl-CoA dehydrogenase
deficiency






dx. CP; dyskinesia, dystonic
tetraparesis








(MADD) (aka Glutaric aciduria
type II)
















treatment (liver tx =
primary treatment)









2c Total body dystonia



































Table 2 Overview of all 54 treatable IEMs presenting as CP mimics identified through systematic literature review (Continued)












treatment (liver tx =
primary treatment)
2b (4) Spastic diplegia, ataxia,
dx. CP





treatment (liver tx =
primary treatment)
2b (4) Cerebellar ataxia





treatment (liver tx =
primary treatment)
2b (4) dx. CP; spastic quadriplegia
Ornithine transcarbamylase
deficiency





treatment (liver tx =
primary treatment)
















613068 FOLR1 (AR) Folinic acid Primary/targeting
underlying
pathophysiology






















4 Spastic quadriplegia dx. CP
Pyridoxamine 5’-phosphate
oxidase deficiency
610090 PNPO (AR) Pyridoxal 5’-phosphate Stabilizing/preventative
treatment
4 Spastic quadriplegia
Emergency regimen is defined as: Adjustment in management of a particular IEM to prevent or minimize metabolic decompensations (and related complications) during illness, periods of decreased intake or increased
energy demand. The mainstay includes high caloric intake, generous fluid management (oral, tube or intravenous), addition/increase of vitamins/co-factors or medications, along with avoidance of substances which
cannot be metabolized in patients with this IEM [24].



















Table 3 Overview of all 13 treatable IEMs presenting as CP mimics identified by clinical experts on our team
Biochemical category Disease name OMIM# Gene(s) Treatment Effect Level of evidence














612718 GATM (AR) Creatine supplements Primary/targeting underlying
pathophysiology
4





Fatty acid oxidation Carnitine palmitoyltransferase I
deficiency
255120 CPT1A (AR) Low-fat, high carbohydrate diet,


















Lipid storage (Leukodystrophy) Cerebrotendinous xanthomatosis
(CTX)
213700 CYP27A1 (AR) Chenodeoxycholic acid Stabilizing/preventative
treatment
4















Urea cycle Carbamoyl phosphate synthetase
(CPS) deficiency









































Table 4 Summary of all treatable IEMs (n = 38, 57%) that can be detected by ‘1st-tier’ metabolic screening tests, which
are affordable and accessible, with the potential to identify multiple IEMs
Blood tests
Acylcarnitine profiles (n = 3) ● MCAD deficiency
● SCAD deficiency
● VLCAD deficiency
Free-to-total serum/plasma carnitine (n = 1) ● Carnitine palmitoyltransferase I
deficiency
Plasma Amino Acids (n = 10) ● Argininemia ● Hartnup disease ● MTHFR Deficiency (&tHcy)
● Argininosuccinate lyase
deficiency
● HHH syndrome ● Ornithine transcarbamylase
deficiency
● Citrullinemia type I ● Maple syrup urine disease ● Phenylketonuria (PKU)
● Citrullinemia, type II
Plasma cholesterol (n = 1) ● Cerebrotendinous xanthomatosis
(CTX)
Serum copper & ceruloplasmin (n = 2) ● Menkes Disease (& urine
deoxypyridinoline)
● Wilson Disease (& urine copper)
Urine tests
Urine creatine metabolites (n = 1) ● GAMT deficiency
Urine oligosaccharides (n = 1) ● Fucosidosis




(MCC) deficiency (& ACP)
● SSADH ● HMG-CoA lyase deficiency
● β-Ketothiolase deficiency ● Glutaric aciduria type I ● mHMG-CoA synthase deficiency




● Cystathionine β-synthase deficiency ● Isovaleric academia ● Propionic academia
● Methylmalonic academia ● SCOT deficiency
Urine purines & pyrimidines (n = 2) ● Lesch-Nyhan syndrome
● Molybdenum cofactor deficiency
Abbreviations include: ACP acylcarnitine profiles, tHcy total homocystine, PAA plasma amnio acids.
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GAMT deficiency, but also Creatine transporter defi-
ciency and AGAT deficiency).Non-treatable IEMs
There are several IEMs that can present as CP mimics
that are not (yet) treatable. These include:
Disorders of amino acids (e.g., Hyperprolinemia type I);
cholesterol (e.g., Mevalonic aciduria); lipids (e.g., FAHN,
Pelizaeus-Merzbacher disease); lysosomal disorders, such
as sphingolipidoses (e.g., GM1/2 gangliosidoses); mito-
chondrial diseases (e.g., Leigh’s disease, sulfite oxidase
deficiency, respiratory chain deficiencies); metals (e.g.,
NBIA1, PLAN); organic acids (e.g., Fumarate Hydratase
Deficiency); peroxisomes (e.g., NALD); and purine and
pyrimidine disorders (e.g., Adenylosuccinase deficiency,
Purine nucleoside phosphorylase deficiency). Some ofthese conditions have emerging treatments, but not an
established standard of care treatment; for example,
Canavan disease, [25] and Gaucher disease, type 3 [26].Discussion
To our knowledge, this is the first comprehensive literature
review to extensively review and compiled all the known
cases of treatable IEMs with co-occurring CP-like symp-
toms (dystonia, movement disorder, basal ganglia lesions,
etc. before age 5 years). A surprisingly high number of CP
mimics were identified, totaling 67 treatable IEMs (54
evidence-based, 13 expert-identified) and 43 non-treatable
IEMs.
Among the treatable IEMs, we made the distinction
between treatments that address primary causes of CP
symptoms versus more secondary causes. For condi-
tions that are primarily treatable, treatment targets the
Table 5 All IEMs (n = 29, 43%) requiring a specific ‘2nd-tier’ test for diagnosis
Biochemical category Disease Diagnostic test
Amino acids PSAT deficiency CSF amino acids (& PAA)
PSPH deficiency (Serine deficiency) CSF amino acids (& PAA)
Late onset non-ketotic hyperglycinemia CSF AA (& Plasma AA)
PHGDH deficiency (Serine deficiency) CSF AA (& Plasma AA)
Cerebral glucose transport Blood brain-barrier glucose-transporter (GLUT1) defect CSF glucose:plasma glucose ratio
Creatine Arginine: glycine amidinotransferase (AGAT) deficiency GATM gene sequencing
Creatine transporter deficiency SLC6A8 gene sequencing
Lipids Abetalipoproteinemia CBC smear, stool samples, fasting lipid profile, MTTP
gene analysis
Lysosomal Krabbe disease WBC enzyme testing
Metachromatic leucodystrophy (MLD) Arylsulfatase-A enzyme activity
Niemann-Pick, type C Filipin staining test (fibroblasts) & NPC1/NPC2 gene
analyses
Mitochondria Coenzyme Q10 deficiency Coenzyme Q10 (fibroblasts) & gene(s) analysis
MELAS Mitochondrial DNA mutation testing
Pyruvate dehydrogenase deficiency Blood & CSF lactate:pyruvate ratio (enzyme activity,
gene(s) analysis)
Neurotransmission Aromatic-L-amino-acid decarboxylase deficiency CSF biogenic amines
DHPR deficiency (biopterin deficiency) CSF neurotransmitters & biopterin loading test
Dopamine transporter deficiency syndrome CSF neurotransmitters
GTPCH1-deficient dopa-responsive dystonia CSF neurotransmitters & biopterin/Phe loading test; clinical
trial of L-dopamine, GTCPH gene analysis
PTPS deficiency (biopterin deficiency) CSF neurotransmitters & biopterin loading test
Sepiapterin reductase deficiency CSF neurotransmitters & biopterin/Phe loading test
Tyrosine hydroxylase deficiency CSF neurotransmitters & TH gene analysis
Vesicular monoamine transporter 2 (VMAT2) CSF monoamine metabolites
Urea cycle Carbamoyl phosphate synthetase (CPS) deficiency CPS gene analysis
N-acetyl-glutamate synthetase deficiency NAGS gene analysis
Vitamins/Co-factors Biotinidase deficiency Biotinidase enzyme activity
Biotin-thiamine-responsive basal ganglia disease SLC19A3 gene analysis
Cerebral folate deficiency syndrome CSF tetrahydrofolate
Hypermanganesemia with dystonia, polycythemia,
and cirrhosis
Whole-blood manganese concentrations, SLC30A10 gene
analysis
Pyridoxamine 5’-phosphate oxidase deficiency Plasma, CSF
The IEMs are listed per biochemical category, with the specific biochemical/genetic diagnostic test per disease. Abbreviations include: CSF cerebrospinal fluid,
PAA plasma amnio acids, Phe phenylalanine.
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example, the neurotransmitter defect Tyrosine hydroxylase
(TH) deficiency is highly amenable to early intervention
treatment with L-dopa shows dramatic improvement and
reversal of symptoms [27,28]. In diseases with secondary
causes of CP symptoms (e.g., MCADD, MSUD, organic
academia, urea cycle deficiency), metabolic crises such as
hypoglycemia or acidosis caused by the metabolic defect
can lead to neurologic sequelae mimicking CP. For these
disorders prevention or stabilization, via emergency regi-
men, medical diets, etc., is best possible outcome.Several IEMs presenting as CP mimics can be identified
with minimally invasive testing. For example in biotinidase
deficiency, the lack of the biotinidase enzyme causes accu-
mulation of organic acid metabolites leading to ketolactic
acidosis and hyperammonemia which can develop CP-
like neurological manifestation (e.g., seisures, hypotonia,
ataxia, feeding problems, cognitive developmental delay,
etc.) [29]. Diagnosis requires minimally invasive testing
(blood sampling for serum enzyme activity) and many
of these symptoms can be alleviated following biotin
supplementation and permanent neurological deficits
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prevented if treated early [29].
Non-treatable IEMs were also reported with the hope
that new treatments might become available in the future.
For example, experimental treatments are currently being
explored in trials for Pantothenate kinase 2-associated
neurodegeneration (PKAN, also known as Hallervorden-
Spatz disease), such as gene therapy, chelation with Defer-
iprone [30] to prevent neurodegeneration caused by brain
iron accumulation.
Although 48% of the IEMs listed can be identified by
newborn screening (NBS) in most Canadian provinces
[31], NBS is not universally standardized; also some
diseases or very mild cases are missed. Therefore, these
treatable IEMs should not be excluded from a differen-
tial diagnosis and are important to look for as part of
clinical investigations for CP. There are also be other
non-IEM disorders that can present with CP symptoms
(e.g. endocrine disorders [32]), which may be useful for
the clinician to be aware.
Whole exome and genome sequencing allows for de-
tection of new CP mimics and, along with other meta-
bolomics approaches and enhanced neuroimaging, will
facilitate research into the phenotypic spectrum and
underlying pathophysiology of these disorders. In the
future, screening for such conditions might be done by
whole exome sequencing, with targeted analysis of the
atypical CP genes, followed by biochemical confirmation
for the IEMs listed here. However, it must be emphasized
that clinical history and exam remain key in the inter-
pretation of genomic data [33]. Furthermore the lumbar
puncture, although invasive, should not be avoided as it
allows for CSF neurotransmitter analysis, which is highly
sensitive and often guides the clinician in further diagnos-
tic and therapeutic decisions.
Despite our attempts to be as thorough as possible in
this systematic review, we acknowledge the limitations
of our study. Many of the IEMs listed are very rare
diseases, with incidence ranging 1:10,000 (PKU) to
1:250,000 or less (GAMT deficiency), and thus, the
number of publications is relatively low and evidence
for treatments is sometimes sparse. As well, it can be
difficult to publish case reports, which could contrib-
ute to a lack of literature evidence and preclude inclu-
sion from our study. We have attempted to account for
this by including expert clinician experience to identify
IEMs that are not yet described in the literature. Des-
pite our efforts to be as inclusive as possible when
compiling the ‘expert’ list based on a working know-
ledge of IEMs that mimic CP (Table 3), we acknow-
ledge that some of the potential candidates may have
been omitted. Finally, neurologic symptoms are often
insufficiently described in metabolic case reports, with
focus often on the biochemical features of an IEM; thiscombined with the broad usage of the term of CP (and its
different forms), the classification of an IEM phenotype as
‘CP mimic’ was challenging and depended on the authors’
expertise.
The extensive number of distinct IEMs that may
mimic CP, each requiring particular diagnostic tests,
places a significant information burden on clinicians.
Here we have gone to extensive lengths to compile all
known IEMs mimicking CP with the hope to help raise
awareness and facilitate diagnostic approach with an
established algorithm [19]. This is by no means meant
as directive but rather, as a supportive tool to the clin-
ician managing children with CP-like symptomatology.
Symptoms which should prompt the clinician to search
for an underlying IEM or other neurogenetic defect
include -but not limited to- the following ‘red flags’:
normal MRI findings imaging; abnormalities isolated
to the globus pallidus; severe symptoms in the absence
of a history of perinatal injury; a pattern of disease inherit-
ance, or consanguinity; neurodevelopmental regression, or
progressively worsening symptomatology; isolated muscu-
lar hypotonia; rigidity (as opposed to spasticity) on phys-
ician examination; paraplegia [33].
Early detection of treatable IEMs and timely interven-
tion is of the utmost importance in order to prevent future
brain insult and manifestation of CP symptoms. Addition-
ally, the determination of the underlying cause of CP,
whether treatable or not, has significance from the point
of view of risk assessment, counselling for families, im-
proved access to community services, better management
of co-morbidities, and the development of prevention and
intervention strategies [13]. This would not only spare suf-
fering of individuals, but would have broader impact in
terms of alleviating the economic and social burden of CP
as well.
As with the TIDE approach of systematic screening
[19], it is our hope that the use of this algorithm will
provide more insight into frequency of IEMs amongst
the CP population, and further increase our understanding
of the etiology of CP. Most importantly, early diagnosis of
IEMs will allow initiation of causal treatment to improve
outcomes via the reduction of possibly prevention of the
the physical burdens of CP.
Conclusions
We provided the first systematic review of treatable
IEMs that can present with symptoms of CP. There are
many single such reports in the literature, however, the
collective incidence of treatable IEM mimicking CP is
unknown and can be determined only by systematic or
large-scale screening studies. Increasing clinician awareness
might be worthwhile, as with timely diagnosis and appro-
priate treatment, these conditions can show improvement
in the primary features, or stabilization and prevention of
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our diagnostic algorithm remains to be determined but
represents a first step towards increased recognition of
potentially treatable conditions in the child with CP.
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